Fibrosis News and Research

RSS

Fibrosis is the growth of fibrous tissue.

New data demonstrates CREON Delayed-Release Capsules improve fat absorption in adults with EPI

Solvay Pharmaceuticals, Inc. announced that new data demonstrate that CREON®( )(pancrelipase) Delayed-Release Capsules significantly improves a key measure of fat absorption in adults with exocrine pancreatic insufficiency (EPI) due to chronic pancreatitis (CP) or pancreatic surgery.

27 Oct 2009

Phase 2a clinical trial in nonsense mutation hemophilia A and hemophilia B initiated

PTC Therapeutics, Inc. (PTC) today announced it is expanding the development of ataluren, an investigational new drug, to a third indication with the initiation of a Phase 2a clinical trial in nonsense mutation hemophilia A (nmHA) and hemophilia B (nmHB).

26 Oct 2009

Additional CFTR inhibitor technology licensed to Napo Pharmaceuticals

Napo Pharmaceuticals, Inc. has in-licensed from the University of California Regents additional small-molecule cystic fibrosis transmembrane conductance regulator (CFTR) inhibitor technology including gastrointestinal (GI) and polycystic kidney disease (PKD) indications.

26 Oct 2009

Inhaling carbon nanotubes can affect outer lining of the lungs

Carbon nanotubes are being considered for use in everything from sports equipment to medical applications, but a great deal remains unknown about whether these materials cause respiratory or other health problems.

26 Oct 2009

Emodin raises hope for treatment of fibrotic liver diseases

In the last decade, advances in the understanding of genes promoting hepatic stellate cell (HSC) activation are impressive. However, there are few breakthroughs in therapeutic intervention of hepatic fibrogenesis. Efficient and well-tolerated antifibrotic drugs are lacking and current treatment of hepatic fibrosis is limited to withdrawal of the noxious agent. Research identifying innocuous antifibrotic agents is of high priority and urgently needed.

24 Oct 2009

AEOL 10150 increases regeneration of GI stem cells: NIAID study results

Aeolus Pharmaceuticals, Inc. announced today that recent experiments in preclinical models conducted by the National Institutes of Health’s (NIH), National Institute of Allergy and Infectious Diseases (NIAID) Radiation/Nuclear Medical Countermeasure Development program have shown that AEOL 10150 can effectively increase regeneration of gastro-intestinal (GI) stem cells, reduce the severity and duration of diarrhea and improve survival when administered at 24 hours after doses of total-body irradiation that produce the lethal GI syndrome.

23 Oct 2009

American Thoracic Society releases new clinical guidelines for pulmonary exacerbation of cystic fibrosis

The American Thoracic Society has released new clinical guidelines for the treatment of exacerbations in cystic fibrosis based on a review of the literature on current clinical practices.

23 Oct 2009

FDA grants Fast Track designation for MacuSight's Perceiva

MacuSight, a developer of innovative therapeutics for the treatment of severe ocular diseases and conditions, today announced that it has received Fast Track designation from the United States Food and Drug Administration (FDA) for Perceiva, the company's proprietary ocular sirolimus product, for the treatment of diabetic macular edema (DME).

21 Oct 2009

NIH grant for Lpath to advance clinical development of its antibody therapeutics

The National Cancer Institute's Small Business Innovation Research (SBIR) Program has awarded Lpath (OTCBB: LPTN), the category leader in lipidomics-based therapeutics, two Phase 1 grants totaling $0.3 million. This follows a series of other SBIR grants awarded to Lpath totaling $6.9 million, including a $3.0 million Phase 2 bridge grant from the NCI awarded this past June.

21 Oct 2009

Patients with chronic hepatitis C can benefit by drinking coffee

Patients with chronic hepatitis C and advanced liver disease who drink three or more cups of coffee per day have a 53% lower risk of liver disease progression than non-coffee drinkers according to a new study led by Neal Freedman, Ph.D., MPH, from the National Cancer Institute (NCI).

20 Oct 2009

Hydra Biosciences and Cubist Pharmaceuticals join to develop novel ion channel drugs

Hydra Biosciences today announced that they have entered into an agreement with Cubist Pharmaceuticals, Inc. for a joint collaboration to develop novel ion channel drugs.

20 Oct 2009

Positive results from Transave's Phase II ARIKACE clinical trials

Transave Inc., today reported additional positive clinical trial results on its lead investigational drug, ARIKACE(TM) (liposomal amikacin for inhalation), an antibiotic that aims to treat chronic lung infections.

20 Oct 2009

Alnara Pharmaceuticals’ announces results of its international Phase 3 study of liprotamase

Alnara Pharmaceuticals, a pharmaceutical company developing novel, non-systemic orally delivered protein therapeutics for the treatment of metabolic diseases, today announced results from an international, Phase 3 open-label, long-term safety study demonstrating the safety and nutritional benefits of liprotamase, a novel pancreatic enzyme replacement therapy (PERT) for patients with cystic fibrosis (CF).

19 Oct 2009

Schering-Plough to present data on boceprevir at the AASLD 2009 Annual Meeting

Schering-Plough announced that data on boceprevir, an investigational hepatitis C virus (HCV) protease inhibitor, will be reported in an oral presentation at the American Association for the Study of Liver Diseases (AASLD) Annual Meeting in Boston, Oct. 30-Nov. 3.

19 Oct 2009

NanoBio's NB-401 preclinical data to be presented at the 2009 North American Cystic Fibrosis Conference

NanoBio Corporation today announced compelling preclinical data for NB-401, a nebulized nanoemulsion-based agent that kills highly drug-resistant strains of bacteria commonly found in cystic fibrosis patients. Currently there are limited treatment options available that effectively address these resistant bacteria. The study results are being presented today at the 2009 Annual North American Cystic Fibrosis Conference (NACFC) in Minneapolis, Minn.

19 Oct 2009

St. Anthony Hospital installs Toshiba America Medical Systems' Vantage Titan MR system

To provide the latest in MR technology to its patient community, St. Anthony Hospital in Gig Harbor, Wash. installed the Vantage TitanTM from Toshiba America Medical Systems, Inc. to offer comprehensive MR patient exams. The new 80-bed St. Anthony hospital is the only full service facility in the area and needed a workhorse MR system to conduct a full range of exams.

18 Oct 2009

Inspire to present its denufosol tetrasodium cystic fibrosis program data at the 23rd NACFC

Inspire Pharmaceuticals, Inc. announced today Inspire scientists and collaborators will present data from the denufosol tetrasodium cystic fibrosis (CF) program in a poster presentation at the 23rd Annual North American Cystic Fibrosis Conference (NACFC) October 15 - 17, 2009 in Minneapolis, MN.

15 Oct 2009

Policymakers urged to preserve access to advanced imaging in final health care reform legislation

Survivors and patients with cancers and heart disease, along with patient advocate organizations and physicians, today urged policymakers to enhance early diagnosis of deadly diseases by preserving access to advanced imaging, such as MRI and CT scans, in final health care reform legislation.

15 Oct 2009

Cystic Fibrosis Foundation honors Greenberg Traurig attorney D. Porpoise Evans

D. Porpoise Evans, a litigation associate in the Miami office of the international law firm Greenberg Traurig P.A., has been named among the "40 Under 40" outstanding lawyers of Miami-Dade County by the Cystic Fibrosis Foundation (CFF). The 40 lawyers will be honored at the CFF benefit dinner on November 20, 2009 at the Intercontinental Hotel in Miami.

14 Oct 2009

University of North Carolina awarded grant to continue research on rare disease-causing gene mutations

The University of North Carolina at Chapel Hill has been awarded a five-year, $6.2 million renewal grant to continue its work as part of the National Institutes of Health's Rare Diseases Clinical Research Network (RDCRN).

14 Oct 2009

Fibrosis News and Research

Further Reading

New data demonstrates CREON Delayed-Release Capsules improve fat absorption in adults with EPI

Phase 2a clinical trial in nonsense mutation hemophilia A and hemophilia B initiated

Additional CFTR inhibitor technology licensed to Napo Pharmaceuticals

Inhaling carbon nanotubes can affect outer lining of the lungs

Emodin raises hope for treatment of fibrotic liver diseases

AEOL 10150 increases regeneration of GI stem cells: NIAID study results

American Thoracic Society releases new clinical guidelines for pulmonary exacerbation of cystic fibrosis

FDA grants Fast Track designation for MacuSight's Perceiva

NIH grant for Lpath to advance clinical development of its antibody therapeutics

Patients with chronic hepatitis C can benefit by drinking coffee

Hydra Biosciences and Cubist Pharmaceuticals join to develop novel ion channel drugs

Positive results from Transave's Phase II ARIKACE clinical trials

Alnara Pharmaceuticals’ announces results of its international Phase 3 study of liprotamase

Schering-Plough to present data on boceprevir at the AASLD 2009 Annual Meeting

NanoBio's NB-401 preclinical data to be presented at the 2009 North American Cystic Fibrosis Conference

St. Anthony Hospital installs Toshiba America Medical Systems' Vantage Titan MR system

Inspire to present its denufosol tetrasodium cystic fibrosis program data at the 23rd NACFC

Policymakers urged to preserve access to advanced imaging in final health care reform legislation

Cystic Fibrosis Foundation honors Greenberg Traurig attorney D. Porpoise Evans

University of North Carolina awarded grant to continue research on rare disease-causing gene mutations

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics

Expanding access to NMR with the Fourier 80 Duo

Latest News